Hepatitis B virus (HBV) infection is a serious
|
|
- Spencer Austin
- 5 years ago
- Views:
Transcription
1 VIRAL HEPATITIS Hepatitis B Virus Genotype G Monoinfection and Its Transmission by Blood Components Michael Chudy, 1 Michael Schmidt, 2 Volker Czudai, 1 Heinrich Scheiblauer, 1 Sigrid Nick, 1 Mira Mosebach, 2 Michael Kai Hourfar, 2 Erhard Seifried, 2 W. Kurt Roth, 2 Elke Grünelt, 3 and C. Micha Nübling 1 An acute hepatitis B virus (HBV) infection was diagnosed in a regular apheresis (plasma/ platelet) donor by the hepatitis B surface antigen (HBsAg) assay and minipool nucleic acid amplification technology (NAT). The acute infection was confirmed by detection of anti- HBc (IgM) and anti-hbs 2 weeks later. The donor showed no clinical symptoms and had normal alanine aminotransferase levels. He had a history of weekly apheresis plasma or platelet donations. Archived material from the donor and the respective recipients was investigated by sensitive HBV NATs as part of a look-back procedure. HBV DNA was detectable in previous donations as well as in two recipients transfused with platelet concentrates. The rare HBV genotype G was identified in all HBV-DNA-positive samples. Strong evidence of genotype G monoinfection was obtained by clonal sequencing, HBV genotype line probe assay, genotype-specific NATs, and restriction pattern analysis. In contrast to previously described genotype G infections, which all appeared as coinfections with genotype A, neither the hepatitis B e antigen (HBeAg) nor anti-hbe was detectable in any of the samples. This shows that HBeAg is dispensable for viral replication. The delay in detecting HBsAg in both the donor and recipient samples may be explained by either decreased genotype G specific synthesis of incomplete viral forms in early HBV infection or the lower sensitivity to genotype G of the current HBsAg assays. In conclusion, this reported case of an HBV infection was caused exclusively by genotype G. (HEPATOLOGY 2006;44: ) Hepatitis B virus (HBV) infection is a serious global health problem, with 2 billion people infected worldwide and 350 million suffering from chronic HBV infection. 1 HBV is a prototype member of the Hepadnaviridae family and consists of a circular, partially double-stranded DNA genome of approximately 3.2 kb. The genome carries four openreading frames (ORFs). The presurface/surface (pre-s/s) region encodes three forms of the viral hepatitis B surface antigen (HBsAg). The precore/core (pre-c/c) region encodes the viral e antigen (HBeAg) and the core protein Abbreviations: HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; NAT, nucleic acid amplification technology; PCR, polymerase chain reaction. From the 1 Paul-Ehrlich-Institut, Langen, Germany; 2 Institute of Transfusion Medicine and Immunohematology, German Red Cross, Johann Wolfgang Goethe University, Frankfurt, Germany; and the 3 Institute of Transfusion Medicine and Immunohematology, German Red Cross, Institute Cottbus, Germany. Received October 5, 2005; accepted March 29, M. Chudy and M. Schmidt contributed equally to this paper. Address reprint requests to: Michael Chudy, Ph.D., Paul-Ehrlich-Institut, Paul- Ehrlich-Str , Langen, Germany. chumi@pei.de; fax (49) Copyright 2006 by the American Association for the Study of Liver Diseases. Published online in Wiley InterScience ( DOI /hep Potential conflict of interest: Nothing to report. (HBcAg). The P coding region is specific for the viral polymerase, and the X-ORF encodes the X protein. HBV is currently classified into eight genotypes (A-H) by sequence divergence with the entire genome exceeding 8%. 2-7 Only a few infections with the rare HBV genotype G have been previously described. All were characterized by simultaneous coinfection with genotype A. The typical features of the genotype G genome are a 36-nucleotide insertion at the 5 end of the C gene and translational stop codons in the pre-c region (codons 2 and 28), preventing HBeAg synthesis. Such sequences had already been described in a U.S. patient coinfected with HIV in 1990 and in an isolate (B1-89) from a French patient in ,9 However, these isolates were not described as a new genotype. Genotype G was detected in 11 of 82 (13%) HBV carriers from Georgia (in the U.S.) and in 2 of 39 (5%) HBV-infected individuals in France. 5 This genotype was also reported in a single patient from Mexico, 6 from Germany, 10 and, recently, from Japan. 11 The Japanese and German patients were also coinfected with HIV type 1. The patient in Japan belonged to a risk group presumed to have acquired HBV and HIV infections while traveling in the United States. All these HBV patients suffered from chronic infection. HBV transmission by transfusion became rare after the introduction of the HBsAg test into blood screening in 99
2 100 CHUDY ET AL. HEPATOLOGY, July 2006 Table 1. Donor History: HBV NAT and Serological Testing of Plasma or Platelet Donations and of Plasma Samples Drawn for Follow-up Investigations Apheresis Donor Date of Donation HBV NAT 1 (copies/ml) * HBV NAT 2 (copies/ml) HBsAg Anti-HBc (total) Anti-HBs (IU/L) ALT (U/L) Plasma 04/04/2003 Negative Negative Negative 17 Plasma 04/10/2003 Negative Negative Negative 15 Plasma 04/17/ <35 Negative 17 Plasma 04/24/ Negative 22 Platelet (1) 04/30/ Negative 22 Platelet (2) 05/09/ Negative 26 Plasma 05/14/2003 4,000 2,875 Negative 19 Platelet (3) 05/19/2003 6,258 Negative 23 Plasma 05/28/2003 8,210 Positive Negative Negative 18 Plasma (Ctrl) 06/04/2003 <6 Positive Negative Plasma (Ctrl) 06/11/ Negative Negative 36 Plasma (Ctrl) 06/18/2003 Negative Negative Positive 18 Plasma (Ctrl) 07/02/2003 Negative Negative Positive Abbreviations: (1), (2), (3), three double-pheresis units that were transfused into four recipients (see Table 2); (Ctrl), control sample for follow-up investigation; ALT, alanine aminotransferase. * Screening laboratory (in-house PCR). Confirmatory laboratory (COBAS TaqMan HBV Test with the High Pure System Nucleic Acid Test). Index donation triggering the look-back investigations. Anti-HBc immunoglobulin M was positive for this plasma sample using the AxSYM Core-M test. Sample was subsequently found to be HBV DNA positive by the COBAS AmpliScreen HBV Test. the early 1970s. Routine HBV nucleic acid amplification technology (NAT) on minipools was introduced on a voluntary basis at some blood transfusion services in order to further improve blood safety by reducing the length of the diagnostic window. 12 However, both screening tests are insufficient for diagnosing all chronic HBV infections because viral load may be below the NAT detection limit and HBsAg may become undetectable some months after the infection. 13 This report describes a recent HBV genotype G infection in a regular blood/plasma donor and the transmission of the virus to two platelet recipients. The look-back procedure identified archived positive donor samples so that the early HBV infection period could be analyzed. Furthermore, the respective recipient materials were available, and more recent blood samples could be taken for further investigation. We were able to confirm the chain of infection, to characterize the implicated viral genotype, and to exclude typical infections by mixed HBV genotypes (G and other) using molecular approaches. Patients and Methods Look-Back Procedure. As the donor (male, 60 years old) sample from May 28, 2003 (index donation), was positive for HBsAg and HBV DNA, a look-back procedure was initiated as required by the German guideline. 14 Archived samples obtained up to 6 months before the last negative donation were identified and repeatedly tested for several HBV markers. Recipients of blood components from the donor in question were traced and tested for HBV markers. The samples available for retrospective investigations are listed in Tables 1 and 2. HBV Serological Markers. The PRISM HBsAg assay (Abbott GmbH & Co. KG, Wiesbaden, Germany) was used for routine HBsAg screening. The cutoff was determined to be 9 pg/ml using the PEI HBsAg standard preparation, subtype ad (1 PEI unit corresponds to 1 ng of immunologically active HBsAg). To detect HBeAg and antibodies to hepatitis core, surface, and e antigens (anti- HBc, anti-hbs, and anti-hbe), the AxSYM HBe 2.0, AxSYM Core, AxSYM Core-M; PRISM HBc, PRISM HBcore; AxSYM AUSAB, and AxSYM Anti-HBe 2.0 tests (all Abbott GmbH & Co. KG, Wiesbaden, Germany) were used. All serological tests were performed according to the manufacturers instructions. To compare HBsAg results, different commercial assays Immulite 2000 HBsAg (DPC, Los Angeles, CA), bio-elisa HBsAg color (Biokit, S.A., Barcelona, Spain), Murex HBsAg version 3 (Abbott/Murex Biotech Ltd., Datford, UK), and IMx HBsAg (Abbott GmbH & Co. KG, Wiesbaden, Germany) were used. HBV NAT. Screening for HBV DNA was performed at the blood screening laboratory with C-gene-specific polymerase chain reaction (PCR; nucleotide positions [nt] , referencing a unique EcoRI site 15 )ina minipool format (n 96 donations) and chemiluminescence analysis. The 95% detection limit of the NAT assay was determined to be about 720 copies/ml, calculated for the single donation entering the minipool. In the two confirmatory laboratories, nested PCR or the TaqMan
3 HEPATOLOGY, Vol. 44, No. 1, 2006 CHUDY ET AL. 101 Table 2. Results of HBV NAT and Serological Testing of Platelet Recipients Recipient Date of Transfusion Platelet Component Date of Testing Recipient HBV NAT 1 HBV NAT 2 (copies/ml) (copies/ml) HBsAg Anti-HBc (total) Anti-HBs (IU/L) ALT (U/L) 1 05/05/2003 (1)* 06/20/2003 Negative Negative Positive /13/2003 (2) 07/01/2003 Negative Negative Negative /20/2003 (3) 3 05/12/2003 (2) 06/11/ Negative 06/23/ Negative Negative 39 06/30/2003 2,670 1,573 Negative Negative /23/2003 >10,000 9,273,200 Positive Negative /20/2003 (3) 06/13/ Negative Negative 06/19/ Negative Negative Negative 07/10/2003 3,900 10,741 Negative Negative Negative 51 07/21/ ,200 16,296 Negative Negative Negative 72 07/31/2003 5,480 9,062 Negative Negative Negative 08/08/2003 6,490 13,890 Negative Positive Negative 41 08/22/ ,120 Negative 77 09/01/2003 2,350 1,152 Negative Positive Negative 09/09/ Negative 49 NOTE. Four recipients were transfused with six potentially infectious platelet concentrates from three thrombapheresis sessions. Abbreviations: (1), (2), (3), three double-pheresis units (see Table 1); ALT, alanine aminotransferase. * Platelets of both bags from a single donation. Screening laboratory (in-house PCR). Confirmatory laboratory (COBAS TaqMan HBV Test with the High Pure System Nucleic Acid Test). assay was used for amplification of the S region (nt and ) and the pre-c/c region (nt ), as previously published. 13,16 HBV DNA was quantified using the COBAS TaqMan HBV Test in combination with the High Pure System Nucleic Acid Test (Roche Diagnostics GmbH, Mannheim, Germany). For the genotypes A-F and genotype G specific PCR approaches, primer pairs were used spanning two regions (nt and ). The well-characterized international reference plasma preparation of HBV genotype A, subtype adw2, was used for retrospective NAT analysis (nucleotide sequence data available in GenBank under accession number AJ012207). 16 Restriction Enzyme Analysis. Amplicons from the nested PCR of the S region (nt ) were digested with HinfI for 1 hour at 37 C following 20 minutes at 80 C for enzyme inactivation. Fragments were separated on an agarose gel and visualized by ethidium bromide staining on a UV illuminator. Sequencing and Phylogenetic Analysis. HBVS-and C-gene-specific primers were used for sequencing plus and minus strands. Amplification products were sequenced directly (TaqMan assay) and after cloning (nested PCR) into the pcr2.1 vector (Invitrogen BV, Leek, The Netherlands) using a BigDye Terminator Cycle Sequencing Ready Reaction Kit on an ABI PRISM DNA 310 sequencer (Perkin Elmer Applied Biosystems, Darmstadt, Germany). Four clones per fragment were sequenced in both directions. S gene sequences (nt ) of prototype genomes of genotypes A-G deposited in GenBank (identified by accession number) were aligned. Phylogenetic analysis was performed as published. 13 Twenty additional clones with a core insert (491 bp) and 10 additional clones with a surface insert (513 bp) derived from the amplified HBV DNA of infected donor sample 05/14 were sequenced using the respective PCR sense primers. Sequencing of Full-Length HBV Genome. Fulllength HBV DNA derived from the donor sample (May 14) was generated by the sequencing of PCR amplicons from 8 overlapping fragments spanning the whole viral genome and cloned into the pcr2.1 vector. Four clones per fragment were sequenced in both directions. A fulllength sequence was compared to published sequences of genotypes A and G, GenBank accession numbers AJ and AF160501, respectively. The new complete sequence is accessible in GenBank under accession number DQ HBV Genotyping Assay. The INNO-LiPA HBV Genotyping assay (Innogenetics N.V., Ghent, Belgium) is a line probe assay designed to differentiate among HBV genotypes A-G by hybridizing type-specific sequences in P gene domains B-C. 17 The new genotype H can also be identified. 18 The assay was performed according to the manufacturer s instructions. Results HBV Markers of Samples Involved in the Transmission Episode. In May 2003 a 60-year-old male apheresis donor tested positive for HBsAg as well as for HBV DNA by minipool PCR in routine screening. Look-
4 102 CHUDY ET AL. HEPATOLOGY, July 2006 back procedures using NAT on archived samples identified six previous donations of his that were HBV DNA positive (three plasmapheresis units, three double-thrombapheresis units; Table 1). All three plasma units were still under inventory hold and could be discarded before further processing. Four recipients had already been transfused with six platelet components derived from three double-pheresis units (Table 2). Two weeks after the initial positive test results, the donor tested positive for immunoglobulin M anti-hbc and anti-hbs. One week later the HBsAg and HBV PCR test results were negative once again. The infection route of the donor was unclear because operations, blood transfusions, travel to high-risk countries, and changing sexual contacts all were denied. Recipient 1 was given platelets of both bags from a single donation (Table 2). Seven weeks after transfusion he was negative for HBsAg and HBV DNA, but positive for anti-hbc and anti-hbs. These data indicate an old, resolved HBV infection rather than a recent one. Recipient 2 received platelet units from two different donations of this infected donor and tested negative for HBsAg and HBV DNA. He was determined to have an anti-hbs titer of 164 IU/L. Past vaccination against HBV seems likely. Recipient 3 had been transfused with a platelet concentrate and tested HBV DNA positive 1 month later (52 copies/ml). The viral DNA concentration increased to more than 9 million copies/ml 4.5 months after transfusion. This recipient tested positive for HBsAg and remained negative for anti-hbc and anti-hbs during this period. Recipient 4 tested positive for HBV DNA (69 copies/ ml) 3 weeks after platelet transfusion. During follow-up, HBV DNA concentration increased and anti-hbc antibodies became detectable 2.5 months after transfusion, whereas tests for HBsAg and anti-hbs remained negative. Recipients 3 and 4 had elevated ALT levels. They died of heart failure. None of the recipients showed clinical symptoms of acute hepatitis. HBV Sequences and Phylogenetic Relatedness Derived from Samples Involved in the Transmission Episode. Two laboratories performed PCR with primer pairs mainly overlapping for the amplified S and C regions. HBV DNA containing plasma samples (from the donor and recipients 3 and 4), which tested positive with the S and C regions as PCR targets, were used for sequencing analysis in order to analyze the putative chain of infection. All examined plasma samples showed 100% sequence identity for both HBV regions, providing strong evidence of transmission by the same viral strain. In contrast to the positive run control (genotype A, subype adw 2; GenBank accession number AJ012207), the sequences from donor and recipient samples were characterized by Fig. 1. Phylogenetic tree constructed on S gene sequences (nucleotide positions ) of 70 HBV strains (retrieved from GenBank) reflecting genotypes A-G, with bootstrap values shown for main branches. HBV sequences from donor, recipient 3, and recipient 4 are indicated by arrows. an insertion of 36 bp after the fifth nucleotide in the C gene and by a translational stop at codon position 28 in the pre-c region (TGG to TAG). A phylogenetic comparison with 70 other HBV genomes representing all known genotypes was performed. Homology percentages and phylogenetic distances were calculated for S-gene nucleotide positions This analysis demonstrated clustering of the sequences from the donor and the recipients in a separate branch representing the HBV genotype G sequences (Fig. 1). Full-Length HBV Sequence of Genotype G. The complete HBV genome derived from the donor was found to consist of 3,245 bp. All characteristic differences with other genotypes were confirmed: translational stop codons at codon positions 2 and 28 of the pre-c region, an insert of 12 amino acids in the amino-terminal part
5 HEPATOLOGY, Vol. 44, No. 1, 2006 CHUDY ET AL. 103 Fig. 2. Strips of INNO-LiPA HBV genotyping assay. Strip 1, donor (05/14); strip 2, recipient 3 (09/ 23); strip 3, recipient 4 (08/08); strip 4, HBV genotype A reference plasma (subtype adw2, GenBank accession number AJ012207); strip 5, HBV-negative plasma sample. Strip lines 3-16 represent genotypes A-G specific probes; lines 1 and 2 are conjugate and amplification controls. Donor and recipients specimens were reactive with genotype G specific line 16 and with known cross-hybridizing line 4. Genotype A positive samples must be reactive with at least two of genotype A specific lines 3-5. and deletion of two amino acids in the carboxy-terminal part of HBcAg, and deletion of three nucleotides in the pre-s1 region. In addition, a further deletion of three nucleotides (TTT) in the overlapping pre-s2/p ORFs resulting in an amino acid deletion of phenylalanine in both proteins was found when compared to the published fulllength sequence of genotype G (AF160501). No frameshift was observed in either ORF because of the presence of four consecutive T nucleotides. The full-length sequence had 87.7% homology with the genotype A sequence (AJ012207). It was nearly identical (99.5% homology) to the first published genotype G reference sequence. 5 Molecular Studies to Identify Mixed Genotype Infection. The results from cloning and sequencing of the amplified HBV DNA, derived from samples of the donor (including additional sequencing of 20 clones with a core insert and 10 clones with a surface insert) and the two recipients, clearly hinted that no sequences of additional HBV genotypes had been identified. Moreover, no sequence showed a recombination of genotype G sequences with sequences from other genotypes. Nevertheless, other methods for direct molecular typing of the HBV genome were performed to challenge these findings. The INNO-LiPA HBV Genotyping line probe assay allows discrimination among HBV genotypes A G. Moreover, LiPA has been shown to identify mixed-genotype infections, which may remain undetected by amplicon sequencing. 17,18 As shown in Fig. 2, the samples of the donor and the two recipients (R3 and R4) were positive for genotype G specific line 16 and for genotype A specific line 4, which was expected to cross-hybridize with the genotype G sequences. By contrast, a mixture of genotypes A and G would be reactive for genotype G (line 16) and at least two of three lines indicative of genotype A (lines 3-5), as explained in the manufacturer s instructions. Because there were not even any faint bands of other genotypes visible, there was no indication of an additional HBV genotype in the donor or recipients samples. Genotypes A-F and G specific PCR was performed with primer pairs for two regions (nt and ). HBV DNA extracted from the donor and recipient samples was amplified exclusively with the genotype G specific primer pairs, whereas, as the control, the genotype A reference sample was amplified with the genotypes A-F primer pairs (Fig. 3). Thus, the results did not give any indication of coinfection of the donor and recipient samples with HBV genotypes other than G. PCR amplification of the pre-s or S region followed by analysis of restriction fragment length polymorphism is another means to distinguish HBV genotypes. Figure 4 shows the results of restriction enzyme analysis with HinfI of the 513-bp amplicon derived from the S gene. It shows a restriction pattern for the reference sample of genotype A (fragment sizes of 7, 19, 34, 175, and 278 bp), which is clearly different from that of the samples of the donor and the recipients (fragment sizes of 7, 19, 34, 48, 175, and 230 bp). The occurrence of an additional restriction site for HinfI in the genotype G sequence of this part of the S gene compared to in the respective genotype A sequence resulted in two fragments 48 and 230 bp in size. Furthermore, the negative test results for HBeAg and anti-hbe in all relevant donor and recipient samples were consistent with a genotype G only infection. This is explained by the absence of an intact pre-c-encoding sequence in genotype G. By contrast, all published genotype G infections appeared as coinfections with ge-
6 104 CHUDY ET AL. HEPATOLOGY, July 2006 Fig. 3. Genotypes A-F and G specific amplification of two regions (nucleotide positions and ) of HBV (M, 100-bp ladder; D, donor; R3, recipient 3; R4, recipient 4; gta, genotype A reference plasma; N, HBV DNA negative control). notype A and were associated with positive HBeAg or anti-hbe results, which again are only explained by the input of genotype A. Discussion This reported case of putative HBV infections was caused exclusively by genotype G. All cases described so far have been coinfections with genotype A. 5,10,19 Two of four recipients transfused with HBV-contaminated platelets were infected with the same rare genotype G. Neither recipient showed any clinical symptoms of acute hepatitis, but both had elevated ALT levels, the cause of which was difficult to determine as both patients died of heart failure 4 6 months after infection. The other two recipients of the platelet concentrates did not develop an HBV infection, possibly because of their HBV-specific immune status: there was evidence of prior vaccination in one recipient and of resolved HBV infection in the other. The lack of genotype G infection after putative HBV vaccination strengthens the concept of cross-genotype protection through genotype A derived vaccines. The identity of the HBV sequences in the donor and the two recipient samples has been demonstrated. These sequences were identical to the first published sequence of genotype G 5 and clustered on a branch separate from the other 6 genotypes in phylogenetic analysis of the S-gene amplicons. The full-length sequence derived from the donor sample consisting of 3,245 bp showed all characteris- Fig. 4. HinfI restriction of a 513-bp amplicon from the S gene of HBV with reference plasma preparation of an HBV genotype A (gta) sample, a donor (D) sample, and recipients 3 (R3) and 4 (R4) samples (M, 100-bp ladder; P, undigested PCR product; HinfI, PCR product digested with HinfI).
7 HEPATOLOGY, Vol. 44, No. 1, 2006 CHUDY ET AL. 105 tic genotype G specific features: 2 stop codons in the pre-c region, insertion of 36 nucleotides at the 5 end of the C gene, and deletion of 1 codon in the pre-s region. The HBV genome of the donor had 87.7% homology with the genotype A sequence (AJ012207) and was nearly identical (99.5% homology) to the first published genotype G sequence (AF160501). We identified a new deletion of an amino acid (F) in the pre-s2/p region with as-yet unclear potential relevance for the biology of the virus. In all previously described cases, HBeAg was detected in the patient samples, although the genotype G genome contains two stop codons in the pre-c region (codons 2 and 28). This finding, puzzling at first glance, is only explained by coinfection with genotype A, missing the stop codons and competent for HBeAg production. 19 Alternative explanations are that the 12 extra amino acids at the N-terminus of the genotype G core protein created a novel signaling sequence directing a fraction of the core protein into the secretory pathway 10 or that nonparticulate core protein-sharing epitopes with HBeAg were detected. 20 However, in our case HBeAg was consistently negative for all tested donor and recipient samples. Neither was any anti-hbe detectable. Thus, these results strongly indicate the dispensability of HBeAg for viral replication. It was assumed that HBeAg is necessary for the induction of a persistent infection. 21 The seroconversion of the donor to anti-hbc and anti-hbs accompanied by the nonreactivity of the HBV DNA shown by NAT most probably reflects recovery from the asymptomatic acute infection. Follow-up investigations of the donor will take place as he gives his consent. For the two recipients follow-up investigations are not possible because of their deaths from heart failure. The serological data are consistent with the sequence analysis of multiple clones derived from amplified sequences of the donor and recipient samples, which exclusively detected genotype G sequences. Moreover, the results of the line probe INNO-LiPA HBV Genotyping assay did not show any indication of an HBV mixedgenotype infection in any of the samples investigated. Independent investigations demonstrated a high correlation between the LiPA assay and other genotyping methods combined with the potential to detect very sensitive mixed-genotype infections. 17 Data from the genotypespecific PCR approaches and from the restriction pattern analysis support the absence of further HBV strains in the donor and recipient samples. In all genotype G cases reported so far, the patients were chronically HBV infected. Here we describe the early period of HBV infection in a donor patient. Although the details of the infection are unknown, HBV genotype G seems to be replication competent without the need for helper viruses. The donor and recipients samples tested negative for antibodies against the hepatitis delta virus (anti-hdv, data not shown). Though very unlikely, HDV coinfection cannot be definitively ruled out because anti-hdv might not yet be detectable in the early infection period. Transfection studies with cloned HBV genomes are currently ongoing to clarify the relative replication competence of different HBV genotypes. Nevertheless, evolutionary relatedness of the new genotype G to genotype A seems likely, as was suggested by the 6-year follow-up study of a French chronic HBV carrier. 9 At the beginning of the study major form B1-83 represented genotype A, whereas 6 years later major form B1-89 was detected as a viral mutant representing a genotype G sequence. This mutant may thus be interpreted as an outcome of selection that might be more capable of escaping the host immune response. 22 For the time being, the geographic origin of pure genotype G and its distribution are unclear. Furthermore, nothing is known about a possible epidemiological link between the reported U.S. and European cases. However, no genotype G cases have been found so far in Japan, in a geographic area with a higher HBV prevalence 23 except for one case imported from the United States. Interestingly, some HIV patients, preferentially by risk group, are coinfected with HBV of rare genotypes. 11 The differences at the nucleic acid level of the S gene of our genotype G with other genotypes reflect only a few unique changes at the amino acid level (A/S45V, Q51L, T63I). The genotype G sequences revealed subtype adw2. No typical HBsAg escape variant is obvious from the sequence analysis. However, because exchanged amino acid positions are N-terminal to the antigen loop, steric alterations cannot be ruled out and may explain reduced sensitivity of the HBsAg tests. Several specimens from the early-infection phase would have been expected to give reactive HBsAg results given the corresponding viral DNA concentrations. This potential lack of sensitivity was also confirmed by five additional HBsAg assays, where again only the plasma sample with the highest DNA ( copies/ml; recipient 3) tested positive for HBsAg (Table 2). We analyzed parallel titration series of this plasma specimen and of the HBV DNA International Standard for NAT assays (97/746, genotype A; NIBSC, Hertfordshire, UK) with the PRISM HBsAg assay. This study revealed a viral DNA concentration corresponding to the HBsAg cutoff of about 600 copies/ml for the WHO standard and of about 24,000 copies/ml for the high-titer recipient sample (data not shown). Normally, an HBsAg excess ratio of more than 1,000:1 between empty HBsAg particles and virions has been
8 106 CHUDY ET AL. HEPATOLOGY, July 2006 described. 24 In our case the ratio was reduced by a factor of more than 10. This considerable difference might reflect either different genotype-specific sensitivities of the HBsAg assays or genotype-specific expression rates of the HBsAg -containing particles. The latter might again result in different ratios of noninfectious viral forms (empty spheres and filamentous HBsAg particles) to viral DNA containing infectious virions. The observed significant decrease in envelope protein secretion of the French B1-89 mutant form was explained by a decrease in the envelope transcripts. The putative down-regulation of these transcripts might be a result of mutations in transcriptional control elements. 22 Because of the increased number of amino acid changes in the pre-s region of genotype G compared to in the amino acid sequences of the other genotypes, an influence on surface antigen synthesis and secretion cannot be ruled out. Further investigations using in vitro systems will provide more information. The observed miscorrelation between detectable HBsAg and HBV DNA levels might lead to a prolonged diagnostic window period and complicate HBV detection during donor screening in transfusion medicine. Therefore, all available donor samples were tested in triplicate with the COBAS AmpliScreen HBV Test (Roche Diagnostics GmbH; data not shown). The earliest detection of HBV DNA was found in the donor sample from April 10, 2003 (two of three replicates were reactive). In this follow-up with frequent specimens ( 1 week between donations), an estimated reduction of the diagnostic window of 7 weeks would be the result of sensitive single-donation HBV NAT. However, minipool PCR of the screening laboratory detected the recent HBV infection quite late, reflecting 8,210 copies of HBV DNA/mL in the index donation. The validated 95% detection limit of this screening NAT assay was about 720 copies/ml. Therefore, even a donation with an HBV DNA concentration of 855 copies/ml would have been expected to give a positive NAT result. Suboptimal primer design (with the C region as target) resulted in a 3 end mismatch as the probable reason for the lower NAT sensitivity of this genotype G sample. By contrast, another in-house minipool TaqMan assay with primers targeted to the S region detected this virus strain in 3 of 4 runs at an HBV DNA concentration of 42 copies/ml (data not shown). Although NAT testing may reduce the length of the diagnostic window significantly, it should be taken into account that apheresis donations usually are available after much shorter intervals than are whole blood donations. In our case platelets or plasma were donated weekly. This high donation frequency increases the potential risk of obtaining several HBVcontaminated window period donations in the absence of highly sensitive NAT systems. The introduction of sensitive NAT systems or larger donation intervals might be considered suitable measures. In conclusion, this report shows that HBV infection may occur exclusively with genotype G and that this infection may be transmitted by transfusion of blood components. No indication of coinfection with a second HBV genotype could be found using a variety of sensitive molecular approaches. The course of infection demonstrated the replication competence of the virus and provided evidence that HBeAg is dispensable for viral replication. Further studies of the obvious relative lack of detection of genotype G HBsAg by screening assays are ongoing. Acknowledgment: We thank Christine Pfannkuch for excellent technical assistance and Ina Plumbaum for critically reading the manuscript. References 1. Zuckerman JN, Zuckerman AJ. Current topics in hepatitis B. J Infect 2000;41: Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988;69: Norder H, Courouce AM, Magnius LO. Molecular basis of hepatitis B virus serotype variations within the four major subtypes. J Gen Virol 1992; 73: Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994;198: Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000;81: Sanchez LV, Maldonado M, Bastidas-Ramirez BE, Norder H, Panduro A. Genotpyes and S-gene variability of Mexican hepatitis B virus strains. J Med Virol 2002;68: Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H. A new Ameridian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002;83: Bhat RA, Ulrich PP, Vyas G. Molecular characterization of a new variant of hepatitis B virus in a persistently infected homosexual man. HEPATOLOGY 1990;11: Tran A, Kremsdorf D, Capel F, Housset C, Dauguet C, Petit MA, et al. Emergence of and takeover by hepatitis B virus (HBV) with rearrangements in the pre-s/s and pre-c/c genes during chronic HBV infection. J Virol 1991;65: Vieth S, Manegold C, Drosten C, Nippraschk T, Günther S. Sequence and phylogenetic analysis of hepatitis B virus genotype G isolated in Germany. Virus Genes 2002;24: Shibayama T, Masuda G, Ajisawa A, Hiruma K, Tsuda F, Nishizawa T, et al. Characterization of seven genotypes (A to E, G and H) of hepatitis B virus recovered from Japanese patients infected with human immunodeficiency virus type 1. J Med Virol 2005;76:24-32.
9 HEPATOLOGY, Vol. 44, No. 1, 2006 CHUDY ET AL Roth WK, Weber M, Seifried E. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting. Lancet 1999;353: Roth WK, Weber M, Petersen D, Drosten C, Buhr S, Sireis W, et al. NAT for HBV and anti-hbc testing increase blood safety. Transfusion 2002; 42: Transfusionsgesetz vom 1. Juli 1998, BGBl I, Valenzuela P, Quiroga M, Zalvidar J, Gray P, Rutter WJ. The nucleotide sequence of the hepatitis B viral genome and the identification of the major viral genes. In: Fields BN, Jaenisch R, Fox CF, eds. Animal Virus Genetics. New York: Academic Press, 1980: Heermann KH, Gerlich WH, Chudy M, Schaefer S, Thommssen R, Eurohep Pathobiology Group. Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. J Clin Microbiol 1999;37: Osiowy C, Giles E. Evaluation of the INNO-LiPA HBV Genotyping assay for determination of hepatitis B genotype. Clin Microbiol 2003;41: Hussain M, Chu CJ, Sablon E, Lok ASF. Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promotor variants. J Clin Microbiol 2003;41: Kato H, Orito E, Gish RG, Bzowej N, Newsom M, Sugauchi F, et al. Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. HEPATOLOGY 2002;35: Milich DR, McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 1986;234: Schaefer S. Hepatitis B virus: significance of genotypes. J Viral Hepat 2005;12: Kremsdorf D, Garreau F, Capel F, Petit MA, Brechot C. In vivo selection of a hepatitis B virus mutant with abnormal viral protein expression. J Gen Virol 1996;77: Kato H, Orito E, Sugauchi F, Ueda R, Gish RG, Usuda S, et al. Determination of hepatitis B virus genotype G by polymerase chain reaction with hemi-nested primers. J Virol Meth 2001;98: Ganem D, Prince AM. Hepatitis B virus infection natural history and clinical consequences. N Engl J Med 2004;350:
Diagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationDiagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)
Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves
More informationRama Nada. - Malik
- 2 - Rama Nada - - Malik 1 P a g e We talked about HAV in the previous lecture, now we ll continue the remaining types.. Hepatitis E It s similar to virus that infect swine, so its most likely infect
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More informationHepatitis B Virus Genotypes: Clinical Implications
Hepatitis B Virus Genotypes : Clinical Implications Subrat Kumar Acharya, Yogesh Batra Professor, Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi 110 029 87 Introduction
More informationHBV PUBLIC HEALTH IMPLICATIONS
جزايری دکتر سيد محمد آزمايشگاه ھپاتيت B -دانشکده بھداشت ويروس شناسی- گروه دانشگاه علوم پزشکی تھران کنگره ارتقا کيفيت- ١٣٩٢ HBV PUBLIC HEALTH IMPLICATIONS 2 billion people have been infected by HBV worldwide.
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationMutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey
Mutants and HBV vaccination Dr. Ulus Salih Akarca Ege University, Izmir, Turkey Geographic Distribution of Chronic HBV Infection 400 million people are carrier of HBV Leading cause of cirrhosis and HCC
More informationHBV : Structure. HBx protein Transcription activator
Hepatitis B Virus 1 Hepatitis B Virus 2 Properties of HBV a member of the hepadnavirus group Enveloped, partially double-stranded DNA viruses, smallest DNA virus Replication involves a reverse transcriptase
More informationDEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE
DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE SoGAT Clinical Diagnostics III 12-13 January 2011, London Michael Chudy Julia Kreß Micha Nübling Paul-Ehrlich-Institut
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationMulticentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status
Journal of Viral Hepatitis, 2006, 13, 329 335 doi:10.1111/j.1365-2893.2005.00692.x Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen
More informationPROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA
PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA SoGAT Clinical Diagnostics II 30 September / 1 October 2009, Istanbul Michael Chudy Julia Kreß C. Micha
More informationHepatitis B Virus Genotype B Is Associated With Earlier HBeAg Seroconversion Compared With Hepatitis B Virus Genotype C
GASTROENTEROLOGY 2002;122:1756 1762 Hepatitis B Virus Genotype B Is Associated With Earlier HBeAg Seroconversion Compared With Hepatitis B Virus Genotype C CHI JEN CHU, MUNIRA HUSSAIN, and ANNA S. F. LOK
More informationCDC website:
Hepatitis B virus CDC website: http://www.cdc.gov/ncidod/diseases/hepatitis/slideset/hep_b/slide_1.htm Relevance Key Features es of Hepatitis t B Virus 250 million people infected worldwide. In areas of
More informationVirion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics
Hepadnaviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Hepatitis viruses A group of unrelated pathogens termed hepatitis viruses cause the vast majority
More informationDetection Different of Genotypes of Hepatitis B virus by Using Genotype- Specific Primers and its Clinical Correlation
ORIGINAL ARTICLE Detection Different of Genotypes of Hepatitis B virus by Using Genotype- Specific Primers and its Clinical Correlation *RUBINA GHANI, HIRA JAVED, HAMZA ALI, MUHAMMAD USMAN, KANWAL SABA,
More informationHEPATITIS VIRUSES. Other causes (not exclusively hepatitis v.)also called sporadic hepatitis: HEPATITIS A(infectious hepatitis)
Dept.of Microbiology/Virology Assist.prof. Shatha F. Abdullah HEPATITIS VIRUSES Medically important hepatitis v. (liver)are: 1.HAV 2.HBV 3.HCV 4.HDV 5.HEV 6.HGV Other causes (not exclusively hepatitis
More informationA polymerase chain reaction-based assay to identify genotype F of hepatitis B virus
Specific Brazilian detection Journal of of Medical HBV strains and Biological from genotype Research F (1999) 32: 45-49 ISSN 0100-879X Short Communication 45 A polymerase chain reaction-based assay to
More informationP0141 HBV 1000 copies/ml genotype reference panel
P0141 HBV 1000 copies/ml genotype reference panel P0141 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents
More informationMicropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ
www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons
More informationHepatitis B Antiviral Drug Development Multi-Marker Screening Assay
Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Background ImQuest BioSciences has developed and qualified a single-plate method to expedite the screening of antiviral agents against
More information2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies
2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies Submitted by: Malaysia Policy Dialogue and Workshop on Attaining a Safe and Sustainable Blood Supply Chain Manila, Philippines 30 September 1
More informationReceived 30 May 2004/Returned for modification 6 August 2004/Accepted 12 August 2004
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2004, p. 5036 5040 Vol. 42, No. 11 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.11.5036 5040.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationHBV Core and Core-Related Antigen Quantitation in Chinese Patients with. Chronic Hepatitis B Genotype B and C Virus Infection
Title page HBV Core and Core-Related Antigen Quantitation in Chinese Patients with Chronic Hepatitis B Genotype B and C Virus Infection Short Title: Quantitation of HBc and HBcrAg in Chinese patients Akinori
More informationHepatitis A-E Viruses. Dr Nemes Zsuzsanna
Hepatitis A-E Viruses Dr Nemes Zsuzsanna Viral Hepatitis - Historical Perspectives Infectious A E Enterically transmitted Viral hepatitis NANB Serum B D C Parenterally transmitted HGV, TTV, SEN, other
More informationCharacterization of Hepatitis B Virus (HBV) Among Liver Patients in Kenya
Characterization of Hepatitis B Virus (HBV) Among Liver Patients in Kenya By MISSIANI OCHWOTO (Medical Research officer, KEMRI) Julius Oyugi 2, Dufton Mwaengo 2, James Kimotho 1 Carla Osiowy 3 and Elijah
More informationHepatitis B viral safety of blood donations: new gaps identified
Editorial Page 1 of 5 Hepatitis B viral safety of blood donations: new gaps identified Wolfram H. Gerlich, Dieter Glebe, Christian G. Schüttler Institute of Medical Virology, National Reference Centre
More informationFrequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India.
Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Cinzia Keechilot, Veena Shenoy 1,V Anil kumar 2,Lalita Biswas 3. MBBS student * Transfusion
More informationImpact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013
Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Overview of SANBS SANBS is a private not for profit company
More informationViral hepatitis Blood Born hepatitis. Dr. MONA BADR Assistant Professor College of Medicine & KKUH
Viral hepatitis Blood Born hepatitis Dr. MONA BADR Assistant Professor College of Medicine & KKUH Outline Introduction to hepatitis Characteristics of viral hepatitis Mode of transmission Markers of hepatitis
More informationCharacterization of Occult Hepatitis B Virus Infection from Blood Donors in China
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1730 1737 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.00145-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Characterization
More informationViral hepatitis. The word hepatitis means inflammation of the liver. There are five main types of viral hepatitis: A, B, C, D, E
Viral hepatitis The word hepatitis means inflammation of the liver There are five main types of viral hepatitis: A, B, C, D, E Hepatitis A and E are typically caused by ingestion of contaminated food or
More informationLearning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.
Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses
More informationViral Hepatitis. Author: Nicolene Naidu
Viral Hepatitis Author: Nicolene Naidu Bachelor of Biological Science (Cellular Biology), Bachelor of Medical Science (Medical Microbiology) (Honours) The liver is the largest gland in the human body and
More informationHAV HBV HCV HDV HEV HGV
Viral Hepatitis HAV HBV HCV HDV HEV HGV Additional well-characterized viruses that can cause sporadic hepatitis, such as yellow fever virus, cytomegalovirus, Epstein-Barr virus, herpes simplex virus, rubella
More informationUses and Misuses of Viral Hepatitis Testing. Origins of Liver Science
Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness
More informationYuen, MF; Sablon, E; Yuan, HJ; Hui, CK; Wong, DKH; Doutreloigne, J; Wong, BCY; Chan, AOO; Lai, CL
Title Author(s) Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus Yuen, MF; Sablon, E; Yuan,
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),
More informationNATURAL HISTORY OF HEPATITIS B
NATURAL HISTORY OF HEPATITIS B AND DIAGNOSTIC: STATE OF THE ART O. BAHRI LABORATORY OF MEDICAL BIOLOGY AZIZA OTHMANA HOSPITAL TUNIS, TUNISIA The 2 nd Congress of The Federation of Arab Societies of Clinical
More informationWHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA
ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2016 WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA
More informationTitle: Reactivation of a Hepatitis B without core antibody: a case report.
JCM Accepted Manuscript Posted Online 28 January 2015 J. Clin. Microbiol. doi:10.1128/jcm.03546-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 1 Title: Reactivation of a Hepatitis
More informationHBV. Next Generation Sequencing, data analysis and reporting. Presenter Leen-Jan van Doorn
HBV Next Generation Sequencing, data analysis and reporting Presenter Leen-Jan van Doorn HBV Forum 3 October 24 th, 2017 Marriott Marquis, Washington DC www.forumresearch.org HBV Biomarkers HBV biomarkers:
More informationErgebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI
Ergebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI NAT for cellular blood components in Germany Definition of minimal NAT sensitivity limit (ID)
More informationOriginally published as:
Originally published as: Ratsch, B.A., Bock, C.-T. Viral evolution in chronic hepatitis B: A branched way to HBeAg seroconversion and disease progression? (2013) Gut, 62 (9), pp. 1242-1243. DOI: 10.1136/gutjnl-2012-303681
More informationTo test the possible source of the HBV infection outside the study family, we searched the Genbank
Supplementary Discussion The source of hepatitis B virus infection To test the possible source of the HBV infection outside the study family, we searched the Genbank and HBV Database (http://hbvdb.ibcp.fr),
More informationOfficial Journal of the European Communities COMMISSION
16.5.2002 EN Official Journal of the European Communities L 131/17 COMMISSION COMMISSION DECISION of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (notified under
More informationInstruction to implement measures for risk minimisation in using HIV-1 NAT test systems
Paul-Ehrlich-Institut P.O. Box 63207 Langen, Germany To: The marketing authorisation holders of cellular blood products and fresh frozen plasma and the holders of authorisations for stem cell preparations
More informationReporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey
Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey This questionnaire consists of three sections: A. Collection and
More informationPhylogenetic, Virological, and Clinical Characteristics of Genotype C Hepatitis B Virus with TCC at Codon 15 of the Precore Region
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2006, p. 681 687 Vol. 44, No. 3 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.3.681 687.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Phylogenetic,
More informationImpact of multi-dye multiplex technology on testing algorithm
Impact of multi-dye multiplex technology on testing algorithm Lydia Blanco. Mª Isabel Gonzalez-Fraile Centro de Hemoterapia y Hemodonación de Castilla y León, España TTI EPIDEMIOLOGICAL DATA IN SPAIN NAT
More informationHepatitis B Virus infection: virology
Hepatitis B Virus infection: virology 167 Falk Symposium: Liver under constant attack from fat to viruses III Falk Gastro-Konferenz 17.-21. September 2008 Congress Centrum Mainz Maura Dandri Department
More informationTrends in molecular diagnostics
Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More informationWHO Parvovirus B19 Genotype Panel
WHO Parvovirus B19 Genotype Panel Mei-ying W Yu, PhD SoGAT XXII Rome, 14-15 April 2011 1 st WHO International Reference Panel for Parvovirus B19 Genotypes In Oct 2009, a plasma-derived parvovirus B19 (B19V)
More informationThe effect of lamivudine- versus tenofovir-containing antiretroviral regimen on hepatitis B infection in a cohort of HIV infected long term survivors
The effect of lamivudine- versus tenofovir-containing antiretroviral regimen on hepatitis B infection in a cohort of HIV infected long term survivors Aura Temereanca 1,2, Luminita Ene 3, Adelina Rosca
More informationHepatitis virus immunity. Mar 9, 2005 Rehermann and Nascimbeni review Crispe review
Hepatitis virus immunity Mar 9, 2005 Rehermann and Nascimbeni review Crispe review HBV & HCV infection outcomes Both viruses cause immune-mediated active and chronic hepatitis HBV Vertical transmission
More informationCorrelations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-hbe Status in HBV Carriers
Int. J. Med. Sci. 2006, 14 Research paper International Journal of Medical Sciences ISSN 1449-1907 www.medsci.org 2006 (1):14-20 2006 Ivyspring International Publisher. All rights reserved Correlations
More informationComparison of Reverse Hybridization, Microarray, and Sequence Analysis for Genotyping Hepatitis B Virus
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2008, p. 1268 1273 Vol. 46, No. 4 0095-1137/08/$08.00 0 doi:10.1128/jcm.01519-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Comparison
More informationUvA-DARE (Digital Academic Repository) Residual infectious risks in blood transfusion Lieshout-Krikke, R.W. Link to publication
UvA-DARE (Digital Academic Repository) Residual infectious risks in blood transfusion Lieshout-Krikke, R.W. Link to publication Citation for published version (APA): Lieshout-Krikke, R. W. (2016). Residual
More informationThis document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
2002D0364 EN 01.07.2012 002.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B COMMISSION DECISION of 7 May 2002 on common technical
More informationHepatitis Serology and Background Notes
Hepatitis Serology and Background Notes Updated and presented by David Dickeson 2012 Collated by Evelyn Crewe 2010 Centre for Infectious Diseases & Microbiology Laboratory Services Institute of Clinical
More informationAlla ricerca del virus nascosto (quando il virus dell epatitie B si occulta )
Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta ) Giovanni Raimondo Epatologia Clinica e Biomolecolare Policlinico Universitario di Messina UI/ml pg/ml HBsAg HBeAg + anti-hbe
More informationHepatitis B. Hepatitis Viruses. Hepatitis Viruses. Hepatitis Viruses
Hepatitis Viruses Hepatitis B History and Overview of Hepatitis B Testing in Australia Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Cytomegalovirus Epstein-Barr Virus Hepatitis Viruses Hepatitis
More informationHEPATITIS B: are escape mutants of concern?
VACCINATION: AN EVOLUTIONARY ENGINE FOR SPECIES? Fondation Mérieux Conference Centre Veyrier-du-Lac, France November 25-27, 2013 HEPATITIS B: are escape mutants of concern? Alessandro ZANETTI Department
More informationCHAPTER 4 RESULTS. showed that all three replicates had similar growth trends (Figure 4.1) (p<0.05; p=0.0000)
CHAPTER 4 RESULTS 4.1 Growth Characterization of C. vulgaris 4.1.1 Optical Density Growth study of Chlorella vulgaris based on optical density at 620 nm (OD 620 ) showed that all three replicates had similar
More informationTHE FREQUENCY OF PRE-CORE GENE MUTATIONS IN CHRONIC HEPATITIS B INFECTION : A STUDY OF MALAYSIAN SUBJECTS
SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH THE FREQUENCY OF PRE-CORE GENE MUTATIONS IN CHRONIC HEPATITIS B INFECTION : A STUDY OF MALAYSIAN SUBJECTS SF Yap 1, PW Wong 1, YC Chen 1 and M Rosmawati 2 1 Department
More informationAnti-HBc: state of the art what is the CORE of the issues?
Anti-HBc: state of the art what is the CORE of the issues? Robert G Gish MD Adjunct Professor Stanford University Medical Director Hepatitis B Foundation Disclosures: See robertgish.com If you wish an
More informationNH2 N N N O N O O P O O O O O
N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects
More informationNAT Screening of Blood Donations in NBC, TRCS
IPFA/PEI, Italy NAT Screening of Blood Donations in NBC, TRCS 2000-2001 Clinical evaluation using COBAS AmpliiScreen HIV & HCV assays, (MP24) window period rate - 1 : 108,768 for HIV-1 and HCV 2002 Routine
More informationChapter 2 Hepatitis B Overview
Chapter 2 Hepatitis B Overview 23 24 This page intentionally left blank. HEPATITIS B OVERVIEW Hepatitis B Virus The hepatitis B virus (HBV) belongs to the Hepadnaviridae family and is known to cause both
More informationInfectious Disease Testing. ULTRA Product Line. Safety is not a Matter of Chance
Infectious Disease Testing ULTRA Product Line Safety is not a Matter of Chance ULTRA Product Line The best answer for HBV, HCV and HIV screening: a global automated solution for safe results. Monolisa
More informationHBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,
More informationR Offergeld, D Faensen, S Ritter, O Hamouda Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
Eurosurveillance, Volume 10, Issue 2, 01 February 2005 Surveillance report HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS C AND HEPATITIS B INFECTIONS AMONG BLOOD DONORS IN GERMANY 2000-2002: RISK OF VIRUS TRANSMISSION
More informationThe most transfusion-relevant viruses that are
TRANSFUSION COMPLICATIONS NAT for HBV and anti-hbc testing increase blood safety W. Kurt Roth, Marijke Weber, Detlev Petersen, Christian Drosten, Sylvia Buhr, Walid Sireis, Wolfgang Weichert, Doris Hedges,
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationHEPATITIS C VIRUS GENOTYPING IN CHRONIC HEPATITIS C PATIENTS
HEPATITIS C VIRUS GENOTYPING IN CHRONIC HEPATITIS C PATIENTS I. Qattan Centres for Hepatology, Royal Free & University College Medical School, London V. Emery Department of Virology, Royal Free & University
More informationProperties of HBV. HBV : Structure. Hepatitis B Virus. Partial dsdna and Enveloped : within the envelope we have (HBsAg) on the surface.
Hepatitis B Virus Partial dsdna and Enveloped : within the envelope we have (HBsAg) on the surface. Also we have Nucleic Acid inside (which is partial ds DNA) and the Nucleocapcid protein which is the
More informationIDENTIFICATION OF HEPATITIS B VIRUS VERTICAL TRANSMISSION FROM FATHER TO FETUS BY DIRECT SEQUENCING
SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH IDENTIFICATION OF HEPATITIS B VIRUS VERTICAL TRANSMISSION FROM FATHER TO FETUS BY DIRECT SEQUENCING Shanshan Wang, Guifu Peng, Mimin Li, Hong Xiao, Pulin Jiang,
More informationHuman diagnostics. Better be Sure: Quantify HDV & HBV viral load. RoboGene product family
Human diagnostics Better be Sure: Quantify HDV & HBV viral load. RoboGene product family 2 RoboGene Product Family Improved patient management: Standardized monitoring of HBV DNA and HDV RNA viral load.
More informationConfirmed (Laboratory Tests) Serum positive for IgM anti-hbc or, hepatitis B surface antigen (HbsAg).
Hepatitis B Hepatitis B is a liver disease that results from infection with the Hepatitis B virus. It can range in severity from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis
More informationDETECTION OF LOW FREQUENCY CXCR4-USING HIV-1 WITH ULTRA-DEEP PYROSEQUENCING. John Archer. Faculty of Life Sciences University of Manchester
DETECTION OF LOW FREQUENCY CXCR4-USING HIV-1 WITH ULTRA-DEEP PYROSEQUENCING John Archer Faculty of Life Sciences University of Manchester HIV Dynamics and Evolution, 2008, Santa Fe, New Mexico. Overview
More informationSupplemental Materials and Methods Plasmids and viruses Quantitative Reverse Transcription PCR Generation of molecular standard for quantitative PCR
Supplemental Materials and Methods Plasmids and viruses To generate pseudotyped viruses, the previously described recombinant plasmids pnl4-3-δnef-gfp or pnl4-3-δ6-drgfp and a vector expressing HIV-1 X4
More informationSince 1973 all blood donations in the Netherlands
ORIGINAL RESEARCH Rare transmission of hepatitis B virus by Dutch donors with occult infection Ryanne W. Lieshout-Krikke, 1 Marian G.J. van Kraaij, 2 Fikreta Danovic, 2 and Hans L. Zaaijer 1 BACKGROUND:
More informationThe ABC s (and D & E s) of the Viral Hepatitides Part 2 DIAGNOSTIC TESTS 3/7/2013
The ABC s (and D & E s) of the Viral Hepatitides Part 2 Thomas Novicki PhD DABMM Clinical Microbiologist Division of Laboratory Medicine novicki.thomas@marshfieldclinic.org Objectives 2 1. Explain the
More informationHepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
More informationResearch Article Clinical Features of Adult Patients with Acute Hepatitis B Virus Infection Progressing to Chronic Infection
International Hepatology, Article ID 358206, 5 pages http://dx.doi.org/10.1155/2014/358206 Research Article Clinical Features of Adult Patients with Acute Hepatitis B Virus Infection Progressing to Chronic
More informationHepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center
Liver International 2006: 26: 796 804 r 2006 The Author Journal compilation r 2006 Blackwell Munksgaard Clinical Studies DOI: 10.1111/j.1478-3231.2006.01297.x Hepatitis B virus genotypes, precore and core
More informationINTERPRETING HEPATITIS B SEROLOGY
INTERPRETING HEPATITIS B SEROLOGY RECOMMENDED WORDING FOR NATIONAL LABORATORIES TO REPORT HEPATITIS B DIAGNOSTIC TEST RESULTS THIS DOCUMENT HAS BEEN ENDORSED BY: Australasian Society for HIV Medicine,
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI
More informationSerological Markers in Chimpanzees
INFECTION AND IMMUNITY, May 1979, p. 352-356 Vol. 24, No. 2 0019-9567/79/05-0352/05$02.00/0 Hepatitis B e-antigen and Its Correlation with Other Serological Markers in Chimpanzees CHUNG-MEI LING,* ISA
More informationHepatitis B Virus hepadnaviruses genome is a small, circular, partly double-stranded DNA
Hepatitis B Virus HBV is the major member of the hepadnaviruses. Other members of this family (Box 65-3) include woodchuck, ground squirrel, and duck hepatitis viruses. These viruses have limited tissue
More informationReal time TaqMan PCR detection and quantitation of HBV genotypes A G with the use of an internal quantitation standard
Journal of Clinical Virology 30 (2004) 86 93 Real time TaqMan PCR detection and quantitation of HBV genotypes A G with the use of an internal quantitation standard J. Weiss, H. Wu, B. Farrenkopf, T. Schultz,
More informationMolecular Testing in the Diagnosis and Management of Chronic Hepatitis B
CLINICAL MICROBIOLOGY REVIEWS, July 2007, p. 426 439 Vol. 20, No. 3 0893-8512/07/$08.00 0 doi:10.1128/cmr.00009-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Molecular Testing
More informationMAJOR ARTICLE JID 2008:198 (1 December) Chen et al.
MAJOR ARTICLE Combined Mutations in Pre-S/Surface and Core Promoter/Precore Regions of Hepatitis B Virus Increase the Risk of Hepatocellular Carcinoma: A Case-Control Study Chien-Hung Chen, 1,2 Chi-Sin
More informationNovel Hepatitis B Virus Genotype A Subtyping Assay That Distinguishes Subtype Aa from Ae and Its Application in Epidemiological Studies
JOURNAL OF VIROLOGY, July 2004, p. 7575 7581 Vol. 78, No. 14 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.14.7575 7581.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Novel Hepatitis
More information